Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05001516 · ClinicalTrials.gov registry record · Phase 1
Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors
A Phase 1 study, sponsored by Turning Point Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT05001516 is a Phase 1 study that has completed, run by Turning Point Therapeutics. The registered enrollment target is 17 participants.
The verdict
NCT05001516, a Phase 1 study, has completed, sponsored by Turning Point Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
A Phase I, First-in-Human, Open-Label, Dose Escalation and Expansion Study of LM-302 in Patients with CLDN18.2-Positive Advanced Solid Tumors
Interventions
- DRUG LM-302
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2021-12-29 |
| Est. Completion | 2024-01-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05001516
The ClinicalTrials.gov registry entry for NCT05001516 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Turning Point Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LM-302 is the first listed.
NCT05001516 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05001516 about?
NCT05001516 is a clinical study titled "Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors". A Phase I, First-in-Human, Open-Label, Dose Escalation and Expansion Study of LM-302 in Patients with CLDN18.2-Positive Advanced Solid Tumors
What is the current status of trial NCT05001516?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2021-12-29. Estimated completion is 2024-01-04.
What interventions are being tested in trial NCT05001516?
The interventions under investigation include: LM-302 (DRUG).
Who is sponsoring clinical trial NCT05001516?
This trial is sponsored by Turning Point Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.